Modified influenza virus for monitoring and improving vaccine efficiency
US7871626B2 · kind B2 · utility
12Cited by
2References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 27, 2006 |
| Grant date | Jan 18, 2011 |
| Priority date | — |
| Expiry date | Jul 27, 2026 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2469/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by altering receptor specificity and/or antibody-antigen binding. HA molecules containing such substitutions will be useful in the development of diagnostic reference viruses and improved influenza vaccines.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.